According to WADA guidelines, the presence of Higenamine (HG) in urine should not be ≥10 ng/mL. HG is widely found in materials used in Chinese herbal medicines as well as food and additives. This paper is the first method wherein a rat model has been used to evaluate the pharmacokinetics of orally administered HG by LC–MS/MS and would be helpful in doping control analysis. The method was found to be linear over a concentration range of 0.5(lower limit of quantification, LLOQ)–500 ng/mL for plasma and 0.5(LLOQ)–1000 ng/mL for urine. The values for intra‐ and inter‐day accuracy and precision did not deviate by >12.25% for HG in plasma and 5.87% in urine. Extraction recoveries of HG were 70.30–86.71% from plasma and 74.93%–79.29% from urine. HG was stable in plasma and urine after the extraction process and when exposed to different storage conditions. The findings of this study could provide some reference value for the assessment of HG misuse and for the control of intake and external application of HG‐related materials (foods and medicinal herbs). Our key findings are that high levels of external application or oral administration of HG‐rich materials may lead to a positive urine test for HG in athletes.

中文翻译：

---

使用LC-MS / MS进行兴奋剂对照分析的大鼠口服组胺的药代动力学研究。

根据WADA指南，尿液中的Higenamine（HG）含量不得≥10 ng / mL。HG广泛用于中草药以及食品和添加剂中。本文是第一种使用大鼠模型通过LC-MS / MS评估口服HG药代动力学的方法，这将有助于掺杂控制分析。发现该方法在血浆浓度为0.5（定量下限，LLOQ）–500 ng / mL，尿液为0.5（LLOQ）–1000 ng / mL的浓度范围内是线性的。血浆中HG和尿液中日间和日间准确性和精密度值的偏差不超过> 12.25％。血浆中HG的提取回收率为70.30–86.71％，尿液中的提取回收率为74.93％–79.29％。提取过程之后以及暴露于不同储存条件下，HG在血浆和尿液中均稳定。这项研究的发现可为评估HG滥用，控制HG相关材料（食品和草药）的摄入和外用提供一些参考价值。我们的主要发现是，大量施用或口服富含HG的材料可能会导致运动员对HG的尿液测试呈阳性。